Device: Desktop


Vyera's research and development resources are aimed at developing novel therapies to treat serious diseases that have been neglected, such as toxoplasmosis and other parasitic infections. Vyera has completed early-stage studies to investigate the safety of VYR-006*, a novel molecule discovered and developed internally, for the treatment of toxoplasmosis.

*The safety and efficacy of the investigational products has not been established by health authorities or approved for use in the United States or globally.

You are about to enter a site that is for US healthcare professionals only. By clicking "Confirm" below, you certify that you are a healthcare professional and that you wish to proceed to the Healthcare Professionals Only section of this site. Products or treatments described on this site are available in the US but may not be available in other countries.

I am a licensed healthcare professional and wish to proceed to the Healthcare Professionals section of this site.